Tags

Type your tag names separated by a space and hit enter

Prostanoids as pharmacological targets in COPD and asthma.
Eur J Pharmacol 2006; 533(1-3):89-100EJ

Abstract

COPD (Chronic Obstructive Pulmonary Disease) and bronchial asthma are two severe lung diseases which represent a major problem of world public health. Leukotrienes and prostanoids play an important role in the pathogenesis of pulmonary diseases. Prostanoids: prostaglandins (PGs) and thromboxane A2 (TXA2), the cyclooxygenase metabolites of arachidonic acid are implicated in the inflammatory cascade that occurs in asthmatic airways. Recently, the roles played by isoprostanes or prostaglandin-like compounds nonenzymatically generated via peroxidation of membrane phospholipids by reactive oxygen species, in particular F2-isoprostanes, in pulmonary pathophysiology have been highlighted. This article aims to provide an overview of the role of prostanoids and isoprostanes in the pathogenesis of COPD and asthma and to discuss the pharmacological strategies developed in prevention and/or treatment of these pathologies.

Authors+Show Affiliations

Department of Pharmacy, University of Namur, Rue de Bruxelles 61, B-5000 Namur, Belgium.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16458293

Citation

Rolin, Stéphanie, et al. "Prostanoids as Pharmacological Targets in COPD and Asthma." European Journal of Pharmacology, vol. 533, no. 1-3, 2006, pp. 89-100.
Rolin S, Masereel B, Dogné JM. Prostanoids as pharmacological targets in COPD and asthma. Eur J Pharmacol. 2006;533(1-3):89-100.
Rolin, S., Masereel, B., & Dogné, J. M. (2006). Prostanoids as pharmacological targets in COPD and asthma. European Journal of Pharmacology, 533(1-3), pp. 89-100.
Rolin S, Masereel B, Dogné JM. Prostanoids as Pharmacological Targets in COPD and Asthma. Eur J Pharmacol. 2006 Mar 8;533(1-3):89-100. PubMed PMID: 16458293.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prostanoids as pharmacological targets in COPD and asthma. AU - Rolin,Stéphanie, AU - Masereel,Bernard, AU - Dogné,Jean-Michel, Y1 - 2006/02/03/ PY - 2005/08/29/received PY - 2005/12/13/accepted PY - 2006/2/7/pubmed PY - 2006/5/12/medline PY - 2006/2/7/entrez SP - 89 EP - 100 JF - European journal of pharmacology JO - Eur. J. Pharmacol. VL - 533 IS - 1-3 N2 - COPD (Chronic Obstructive Pulmonary Disease) and bronchial asthma are two severe lung diseases which represent a major problem of world public health. Leukotrienes and prostanoids play an important role in the pathogenesis of pulmonary diseases. Prostanoids: prostaglandins (PGs) and thromboxane A2 (TXA2), the cyclooxygenase metabolites of arachidonic acid are implicated in the inflammatory cascade that occurs in asthmatic airways. Recently, the roles played by isoprostanes or prostaglandin-like compounds nonenzymatically generated via peroxidation of membrane phospholipids by reactive oxygen species, in particular F2-isoprostanes, in pulmonary pathophysiology have been highlighted. This article aims to provide an overview of the role of prostanoids and isoprostanes in the pathogenesis of COPD and asthma and to discuss the pharmacological strategies developed in prevention and/or treatment of these pathologies. SN - 0014-2999 UR - https://www.unboundmedicine.com/medline/citation/16458293/Prostanoids_as_pharmacological_targets_in_COPD_and_asthma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-2999(05)01389-0 DB - PRIME DP - Unbound Medicine ER -